Drug Type Biological products |
Synonyms DF 2211, DF2211 |
Target |
Action inhibitors |
Mechanism BAFF-R inhibitors(B-cell activating factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Lupus Nephritis | Preclinical | United States | 01 Mar 2026 | |
| Pemphigoid, Bullous | Preclinical | United States | 01 Mar 2026 | |
| Polycythemia Vera | Preclinical | United States | 01 Mar 2026 | |
| Sjogren's Syndrome | Preclinical | United States | 01 Mar 2026 |





